11138600001
Roche
Interleukin-6, human (hIL-6)
recombinant (E. coli)
Synonyme(s) :
hIL-6, interleukin-6 human
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352207
Produits recommandés
Source biologique
human
Niveau de qualité
Produit recombinant
expressed in E. coli
Pureté
>98% (SDS-PAGE)
Forme
solution
Puissance
<0.01 ng/mL EC50
Poids mol.
20,600 Da
Conditionnement
pkg of 200,000 U (2 μg, 1 ml)
Fabricant/nom de marque
Roche
Conditions de stockage
avoid repeated freeze/thaw cycles
Technique(s)
cell culture | hybridoma: suitable
Impuretés
<0.1 EU/μgtested (LAL test)
Numéro d'accès UniProt
Température de stockage
−20°C
Informations sur le gène
human ... IL6(3569)
Description générale
Interleukin-6, human (hIL-6), is produced in E. coli and purified by standard chromatographic techniques.
Spécificité
Recombinant IL-6, human is effective on mouse and human cells.
IL-6, a 26 kD protein, also known as B-cell stimulatory factor 2 (BSF-2, BCDF), interferon-β2 (IFN-β2), hybridoma/plasmacytoma growth factor (H(P)GF), and hepatocyte-stimulating factor is produced by many cell types (e.g., T-cells, monocytes, fibroblasts, endothelial cells). IL-6 induces the terminal maturation of activated B-cells into antibody-producing cells (B-cell differentiation activity. The hepatic acute phase response is induced by IL-6 (hepatocyte-stimulating activity). It was shown that IL-6 and IL-3 act synergistically to support the proliferation of hematopoietic stem cells (hemapoietic activity), however, IL-6 does not have antiviral activity, although it has been called IFN-β2. High affinity receptors for IL-6 are found on many cell types.
IL-6, a 26 kD protein, also known as B-cell stimulatory factor 2 (BSF-2, BCDF), interferon-β2 (IFN-β2), hybridoma/plasmacytoma growth factor (H(P)GF), and hepatocyte-stimulating factor is produced by many cell types (e.g., T-cells, monocytes, fibroblasts, endothelial cells). IL-6 induces the terminal maturation of activated B-cells into antibody-producing cells (B-cell differentiation activity. The hepatic acute phase response is induced by IL-6 (hepatocyte-stimulating activity). It was shown that IL-6 and IL-3 act synergistically to support the proliferation of hematopoietic stem cells (hemapoietic activity), however, IL-6 does not have antiviral activity, although it has been called IFN-β2. High affinity receptors for IL-6 are found on many cell types.
Application
Recombinant IL-6, human, is a growth factor for murine and human B-cells. It can be used to replace feeder cells in the preparation of murine and human hybridomas.
Actions biochimiques/physiologiques
Interleukin-6 participates in several pleiotropic functions in various types of cells through its specific receptor (IL-6-R). It has been suggested that interleukin-6 may participate in the interaction between neuroendocrine and immune system by activating adrenocorticotropic hormone secretion. It has also been reported that IL-6 stimulates the bonding of receptor (IL-6-R) with a non-ligand-binding membrane glycoprotein, gp130.
Qualité
Purity: 95% pure as determined by HPLC or SDS-PAGE [Endotoxin level: <0.1 EU/μg (LAL-test), <10 EU/ml (LAL-test).
Note: 1 EU corresponds to 0.1 ng
Note: 1 EU corresponds to 0.1 ng
Séquence
Chain Length 184 AA
The primary structure of recombinant human IL-6 is identical to that of natural human IL-6 (one polypeptide chain, 184 amino acids), however, it contains an altered sequence within the first 15 amino-terminal amino acids.
Définition de l'unité
EC50 definition: The amount of hIL-6 that is required to support half-maximal stimulation of cell proliferation (MTT cleavage) with 7TD1 cells (1 unit equals <0.01 ng).
Forme physique
Solution, filtered through 0.2 μm pore size membrane.
Notes préparatoires
Working concentration: 10 to 100 U/ml (0.1 1 ng/ml)
10 to 100 U/ml (0.1 to 1 ng/ml)
A concentration of 100 U/ml (1 ng/ml) is recommended for the preparation of B-cell hybridomas
Working solution: Dilute the concentrated IL-6 solution (200,000 U/ml) with PBS or culture medium containing 1 mg/ml BSA [or HSA (human serum albumin)] or 1 to 10% serum.
Storage conditions (working solution): -15 to -25 °C
Store the solution in aliquots at -15 to -25 °C.
Note: Avoid repeated freezing and thawing.
10 to 100 U/ml (0.1 to 1 ng/ml)
A concentration of 100 U/ml (1 ng/ml) is recommended for the preparation of B-cell hybridomas
Working solution: Dilute the concentrated IL-6 solution (200,000 U/ml) with PBS or culture medium containing 1 mg/ml BSA [or HSA (human serum albumin)] or 1 to 10% serum.
Storage conditions (working solution): -15 to -25 °C
Store the solution in aliquots at -15 to -25 °C.
Note: Avoid repeated freezing and thawing.
Reconstitution
Dilute the concentrated IL-6 solution (200,000 U/ml) with PBS or culture medium containing 1 mg/ml BSA [or HSA (human serum albumin)] or 1 to 10% serum.
Remarque sur l'analyse
Specific activity/EC50: >1 x 108 U/mg, <0.01 ng/ml (hIL-6, NIBSC, interim standard, 88/514), at least the same specific activity (EC50) compared to the indicated standard is guaranteed.
Autres remarques
For life science research only. Not for use in diagnostic procedures.
Code de la classe de stockage
12 - Non Combustible Liquids
Classe de danger pour l'eau (WGK)
nwg
Point d'éclair (°F)
does not flash
Point d'éclair (°C)
does not flash
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
H Kikutani et al.
Journal of immunology (Baltimore, Md. : 1950), 134(2), 990-995 (1985-02-01)
Stimulation of human B lymphoblastoid cell lines, CESS and SKW6-CL4 with BCDF induced an increase in IgG- and IgM-secreting cells, as well as a slight increase in IgG and IgM expression on their respective surfaces. Biosynthetic labeling demonstrated that BCDF
R Bazin et al.
Journal of immunological methods, 116(2), 245-249 (1989-01-17)
The addition of macrophage feeder cells or conditioned medium has been shown to increase the yield of murine hybridomas obtained after the fusion of myeloma cells and activated B lymphocytes. It has been shown recently that the conditioned medium contains
B cell growth and differentiation factors.
K Brooks et al.
Methods in enzymology, 116, 372-379 (1985-01-01)
Y Naitoh et al.
Biochemical and biophysical research communications, 155(3), 1459-1463 (1988-09-30)
In order to assess the effect of interleukin-6 on the hypothalamo-pituitary-adrenal axis, we administered recombinant human interleukin-6 to conscious, freely-moving rats. The intravenous injection of interleukin-6 significantly increased the plasma level of adrenocorticotropic hormone 30 min after the injection in
J Gordon et al.
Immunology today, 8(11), 339-344 (1987-01-01)
The need to activate B lymphocytes on antigen challenge is tempered by the requirement that the response is terminated when the challenge has been negotiated. Regulation is probably mediated via the interaction of soluble factors with surface receptors. Here, John
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique